Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines

Journal of Medical Virology

Volumn 60, Issue 1, 2000, Pages 1-7

  Van Herck, K ^a   Beutels, P ^a   Van Damme, P ^a   Beutels, M ^a   Van Den Dries, J ^a   Briantais, Ph ^b   Vidor, E ^c  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Biometry Department   (France)

^c Medical Affairs   (France)

Author keywords

Antibody persistence; Long term immunogenicity; Mathematical models

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; INACTIVATED VIRUS VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; VACCINATION;

ADOLESCENT; ADULT; FEMALE; HEPATITIS A VACCINES; HEPATITIS A VIRUS, HUMAN; HEPATITIS ANTIBODIES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; MODELS, IMMUNOLOGICAL; TIME FACTORS; VACCINATION; VACCINES, INACTIVATED; VIRAL HEPATITIS VACCINES;

EID: 0033991902     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(200001)60:1<1::AID-JMV1>3.0.CO;2-H     Document Type: Article

References (21)

1. Berger R, Just M. 1992. Vaccination against hepatitis A: control 3 years after the first vaccination. Vaccine 10:295.
2. Bovier P, Farinelli T, Loutan L, Herzog C, Glueck R. 1997. Long-term immunogenicity following immunization with a virosome hepatitis A vaccine. Fifth International Conference on Travel Medicine, Abstract 129 (Geneva, Switzerland, 24-27 March 1997), p 136.
3. Centers for Disease Control and Prevention. 1996. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal WkIy Rep 45(No. RR-15):1-30.
4. Goilav C, Zuckerman J, Lafrenz M, Vidor E, Lauwers S, Ratheau C, Benichou G, Zuckerman A. 1995. Immunogenicity and safety of a new inactivated hepatitis A vaccine. J Med Virol 46:287-292.
5. Goilav C, Zuckerman J, Lafrenz M, Vidor E, Lauwers S, Ratheau C, Benichou G, Zuckerman A. 1997. Persistence of antibodies after inactivated hepatitis A vaccines in a comparative study. J Infect 34:158.
6. Hadler SC, McFarland L. 1986. Hepatitis in day-care centers: epidemiology and prevention. Rev Infect Dis 8:548-557.
7. Hollinger F. 1989. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 87(Suppl 3A):36S-40S.
8. Lea A, Balfour J. 1997. Virosomal hepatitis A vaccine (strain RG-SB). BioDrugs 7:232-248.
9. Maiwald H, Jilg W, Bock HL, Löscher T, von Sonnenburg F. 1997. Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine. Vaccine 15:346-348.
10. Miller W, Clark W, Hurni W, Kuter B, Schofield T, Nalin D. 1993. Sensitive assays for hepatitis A antibodies. J Med Virol 41:201-204.
11. Peetermans J. 1992. Production, quality control and characterization of an inactivated hepatitis A vaccine. Vaccine 10:S99-S101.
12. Reuman P, Kubilis P, Hurni W, Brown L, Nalin D. 1997. The effect of age and weight on the response to formalin inactivated, alumadjuvanted hepatitis A vaccine in healthy adults. Vaccine 15: 1157-1161.
13. Simonsen O, Kristiansen M, Aggerbeck H, Hau C, Heron I. 1996. Fall-off in immunity following diphtheria revaccination - an 8 year follow-up study. Acta Pathol Microbiol Immunol Scand 104: 921-925.
14. Strady A, Lang J, Lienard M, Blondeau C, Jaussaud R, Plotkin S. 1998. Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. J Infect Dis 177:1290-1295.
15. Totos G, Gizaris V, Papaevangelou G. 1997. Hepatitis A vaccine: persistence of antibodies 5 years after the first vaccination. Vaccine 15:1252-1253.
16. Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A. 1994. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 44:446-451.
17. Van Damme P, Van Herck K, Thoelen S, Meheus A. 1998. Long-term immunogenicity of a high potency inactivated hepatitis A vaccine. J Hepatol 28(Suppl 1):113.
18. Vidor E, Fritzell B, Plotkin S. 1996. Clinical development of a new inactivated hepatitis A vaccine. Infection 24:447-458.
19. West D, Calandra GB. 1996. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 14:1019-1027.
20. Wiedermann G, Kundi M, Ambrosch F, Safary A, D'Hondt E, Delem A. 1997. Inactivated hepatitis A vaccine: long-term antibody persistence. Vaccine 15:612-615.
21. ®. J Med Virol 49:235-241.